Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jul;41(7):1607–1608. doi: 10.1128/aac.41.7.1607

In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.

J M Meyer 1, S Ryu 1, S L Pendland 1, L H Danziger 1
PMCID: PMC163970  PMID: 9210696

Abstract

The activity of clarithromycin-14-hydroxyclarithromycin (2:1 ratio) and bismuth subsalicylate or amoxicillin against Helicobacter pylori was determined by the checkerboard technique in vitro. Clarithromycin-14-hydroxyclarithromycin and amoxicillin resulted in additive effects in 7 of 22 isolates, compared to 14 of 22 isolates when bismuth subsalicylate was substituted for amoxicillin. Synergy was not demonstrated and is probably not responsible for the clinical success of treatment combinations containing clarithromycin.

Full Text

The Full Text of this article is available as a PDF (109.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cederbrant G., Kahlmeter G., Schalén C., Kamme C. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother. 1994 Dec;34(6):1025–1029. doi: 10.1093/jac/34.6.1025. [DOI] [PubMed] [Google Scholar]
  2. Goodwin C. S., Blake P., Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother. 1986 Mar;17(3):309–314. doi: 10.1093/jac/17.3.309. [DOI] [PubMed] [Google Scholar]
  3. Hardy D. J., Hanson C. W., Hensey D. M., Beyer J. M., Fernandes P. B. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother. 1988 Nov;22(5):631–636. doi: 10.1093/jac/22.5.631. [DOI] [PubMed] [Google Scholar]
  4. Hardy D. J., Swanson R. N., Rode R. A., Marsh K., Shipkowitz N. L., Clement J. J. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother. 1990 Jul;34(7):1407–1413. doi: 10.1128/aac.34.7.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hoover W. W., Barrett M. S., Jones R. N. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin. Diagn Microbiol Infect Dis. 1992 Mar-Apr;15(3):259–266. doi: 10.1016/0732-8893(92)90122-a. [DOI] [PubMed] [Google Scholar]
  6. Nagate T., Numata K., Hanada K., Kondo I. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics. J Clin Gastroenterol. 1990;12 (Suppl 1):S135–S138. doi: 10.1097/00004836-199001001-00023. [DOI] [PubMed] [Google Scholar]
  7. Soll A. H. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA. 1996 Feb 28;275(8):622–629. doi: 10.1001/jama.275.8.622. [DOI] [PubMed] [Google Scholar]
  8. Van Caekenberghe D. L., Breyssens J. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother. 1987 Sep;31(9):1429–1430. doi: 10.1128/aac.31.9.1429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Vogt K., Warrelmann M., Hahn H. The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori. Zentralbl Bakteriol. 1989 Sep;271(3):304–310. doi: 10.1016/s0934-8840(89)80028-3. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES